{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:47:00Z","timestamp":1769597220720,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.molimm.2015.02.033","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T12:50:11Z","timestamp":1428929411000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"PA","title":["Clinical overview of anti-CD19 BiTE\u00ae and ex vivo data from anti-CD33 BiTE\u00ae as examples for retargeting T cells in hematologic malignancies"],"prefix":"10.1016","volume":"67","author":[{"given":"Gerhard","family":"Zugmaier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2015.02.033_bib0005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/leu.2012.341","article-title":"T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct","volume":"27","author":"Aigner","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0015","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0020","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-08-2650","article-title":"Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans","volume":"69","author":"Baessler","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.molimm.2015.02.033_bib0025","first-page":"22","article-title":"BiTE: teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.molimm.2015.02.033_bib0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1358\/dof.2008.033.02.1172578","article-title":"BiTE: a new class of antibodies that recruit T-cells","volume":"33","author":"Baeuerle","year":"2008","journal-title":"Drugs Future"},{"key":"10.1016\/j.molimm.2015.02.033_bib0035","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.molimm.2015.02.033_bib0040","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0045","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0050","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molimm.2015.02.033_bib0055","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J. Immunother."},{"key":"10.1016\/j.molimm.2015.02.033_bib0060","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2015.02.033_bib0065","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0075","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0080","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0085","first-page":"30","article-title":"Bakterien gegen Tumoren","volume":"7","author":"DeWeerdt","year":"2014","journal-title":"Spek. Wissensch."},{"key":"10.1016\/j.molimm.2015.02.033_bib0090","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19\u2212\/CD3\u2212 bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0095","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molimm.2015.02.033_bib0100","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0105","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","article-title":"Targeting T cells to tumor cells using bispecific antibodies","volume":"17","author":"Frankel","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molimm.2015.02.033_bib0120","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.molimm.2015.02.033_bib0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"issue":"abstr","key":"10.1016\/j.molimm.2015.02.033_bib0135","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/jco.2013.31.15_suppl.3051","article-title":"Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL)","volume":"31","author":"Hijazi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19\u2212\/CD3\u2212 bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molimm.2015.02.033_bib0145","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.molimm.2015.02.033_bib0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","article-title":"Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity","volume":"18","author":"Jedema","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0155","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0160","first-page":"2725","article-title":"T cell responses during long-term continuous infusion of MT103 (MEDI-538; anti-CD19 BiTE) in patients with relapsed B-NHL: data from dose-escalation study MT103-104","volume":"108","author":"Klinger","year":"2006","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"10.1016\/j.molimm.2015.02.033_bib0165","first-page":"174","article-title":"Pharmacodynamic analyses of peripheral blood from relapsed B-NHL patients treated with anti-CD19\/-CD3 bispecific BiTE\u00ae antibody blinatumomab","volume":"94","author":"Klinger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.molimm.2015.02.033_bib0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/leu.2014.186","article-title":"Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse","volume":"29","author":"Kohnke","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0175","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0180","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody\u2013drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/imt.12.145","article-title":"Current strategies in immunotherapy for acute myeloid leukemia","volume":"5","author":"Lichtenegger","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.molimm.2015.02.033_bib0190","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0195","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0200","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0205","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1002\/anie.201405353","article-title":"Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia","volume":"53","author":"Lu","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.molimm.2015.02.033_bib0210","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2015.02.033_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.molimm.2015.02.033_bib0225","first-page":"319","article-title":"Recombinant bispecific antibodies for cellular cancer immunotherapy","volume":"9","author":"Muller","year":"2007","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.molimm.2015.02.033_bib0230","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molimm.2015.02.033_bib0235","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0240","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0245","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2015.02.033_bib0250","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.molimm.2015.02.033_bib0255","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/jco.2013.31.15_suppl.7020","article-title":"Immunopharmacodynamic response to blinatumomab in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL)","volume":"31","author":"Schub","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0260","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2015.02.033_bib0265","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2141.2009.08033.x","article-title":"Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells","volume":"148","author":"Stein","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0270","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0275","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0285","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL)","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0290","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0295","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.molimm.2015.02.033_bib0300","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/17474086.2014.896190","article-title":"Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia","volume":"7","author":"Walter","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.molimm.2015.02.033_bib0305","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2015.02.033_bib0310","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory (r\/r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase 1\/2 study","author":"Whitlock","year":"2014","journal-title":"Int. Soc. Paediatric Oncol. Annu. Congr."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589015000887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589015000887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:34:15Z","timestamp":1598906055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589015000887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0161589015000887"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2015.02.033","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical overview of anti-CD19 BiTE\u00ae and ex vivo data from anti-CD33 BiTE\u00ae as examples for retargeting T cells in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2015.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}